Single Center Study of Apremilast for the Treatment of Hidradenitis Suppurativa

NCT02695212 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Hidradenitis Suppurativa

Interventions

DRUG: Apremilast

Sponsor

Florida Academic Dermatology Centers